Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Veracyte is a financially sound company with strong product offerings, including TrueMRD and Percepta, and established partnerships. With a focus on R&D and expansion in key markets, such as urology, endocrinology, and breast cancer, there is potential for growth. While facing some competition and legal challenges, the company's evidence-based products and strong financial position make them a promising investment opportunity.

Bears say

Veracyte is a genomic diagnostics company with a negative outlook due to potential market saturation for its Afirma test and increased competition in the urology diagnostics market. While the company has a strong margin base and cash generation potential, future investments may limit margin expansion. Veracyte also faces risks related to reimbursement and payer concentration, as well as potential legal litigation. However, the company has potential upside drivers in the form of sales growth from its Decipher and Afirma tests, as well as the potential for increased cash flow.

Veracyte (VCYT) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 9 analysts, Veracyte (VCYT) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.